11 December 2024 - NICE has published final evidence-based recommendations on the use of elranatamab (Elrexfio) for the treatment of adults with relapsed and refractory multiple myeloma after three or more treatments.

Elranatamab is recommended with managed access as an option for the treatment of adults with relapsed and refractory multiple myeloma only after three or more lines of treatment (including an immunomodulatory agent, a proteasome inhibitor and an anti‑CD38 antibody) when the multiple myeloma has progressed on the last treatment. It is only recommended if the conditions in the managed access agreement for elranatamab are followed.

Read NICE technology appraisal guidance